NIH-funded clinical trial finds cholesterol-lowering treatment reduced cardiovascular events by 35%.
A National Institute of Health-supported study found that statins, a class of cholesterol-lowering medications, may offset the high risk of cardiovascular disease in people living with HIV by more than a third, potentially preventing one in five major cardiovascular events or premature deaths in this population. People living with HIV can have a 50–100% increased risk for cardiovascular disease. The findings are published in the New England Journal of Medicine.
Comments are closed.